Research and development is generally not an intangible asset under U.S. accounting rules. Companies following U.S. GAAP expense internal R&D costs in the year they are incurred, so the spending never lands on the balance sheet. International Financial Reporting Standards take a split approach: research-phase costs are expensed, but development-phase costs must be capitalized as intangible assets once a project meets six specific tests. And in both systems, certain things that come out of R&D work — patents, acquired unfinished research, and some software — do get recorded as intangible assets in their own right.
Why US GAAP Keeps R&D Off the Balance Sheet
Accounting Standards Codification Topic 730 requires companies to expense every dollar of internal research and development in the year it’s spent.1Internal Revenue Service. FAQs – IRC 41 QREs and ASC 730 LBI Directive The costs hit the income statement, not the balance sheet. The Financial Accounting Standards Board wrote the rule this way because the link between current R&D spending and future profits is speculative. A drug trial can consume millions and produce nothing marketable, and carrying that spending as an asset would put value on the balance sheet that may never materialize.
The rule sweeps in the full range of R&D outlays: researcher wages, laboratory supplies, project-specific equipment, and payments to outside contractors for research services. A promising project gets no different treatment than a speculative one. Spend $2 million this year on a prototype and the whole $2 million reduces current-year income.2Internal Revenue Service. IRC 41 ASC 730 Research and Development Costs Some activities that look like R&D fall outside the definition and aren’t caught by the rule at all, including routine product testing, quality control, market research, and minor tweaks to existing products.
Even though nothing is capitalized, disclosure is still required. Companies must show total R&D costs either as a separate income statement line or in the notes to the financial statements, for every period presented.1Internal Revenue Service. FAQs – IRC 41 QREs and ASC 730 LBI Directive Investors read that figure to gauge how much a company is putting into future innovation, but none of it appears among the company’s assets.
When R&D Can Be an Intangible Asset Under IFRS
International Accounting Standard 38 splits the innovation process into two phases and treats them differently. Research-phase costs are expensed as incurred, matching the U.S. approach and for the same reason: at that stage, a company cannot yet show that any future asset will result. Development-phase costs are different. IAS 38 requires them to be capitalized as intangible assets on the balance sheet once all six of the following conditions are met:3IFRS Foundation. IAS 38 Intangible Assets
- The company can show it is technically capable of finishing the asset so it will be available for use or sale.
- Management intends to complete the asset and either use it or sell it.
- The company has the ability to put the finished asset to work commercially.
- The company can demonstrate probable future economic benefits, such as through evidence of a market for the output.
- Adequate technical, financial, and other resources exist to finish development and bring the asset to market.
- The company can reliably measure the costs attributable to the asset during development.
The hard part is drawing the boundary. A pharmaceutical company running early-stage clinical trials is still in the research phase. Once the company can show the drug can be manufactured at scale, has regulatory clearance in sight, and has a projected viable market, development-phase costs start accumulating on the balance sheet. That judgment is one of the most contested areas in IFRS accounting, and auditors examine it closely because capitalizing too early inflates reported assets.
Things That Come Out of R&D and Do Sit on the Balance Sheet
Even under GAAP’s strict expensing rule, several categories connected to R&D end up as intangible assets. The distinction is that these items either have an objective market price, a completed legal status, or are covered by narrower rules that override the general treatment.
Patents
When R&D work produces a patentable invention, the patent itself is an intangible asset. The recorded value covers only the direct costs of getting legal protection: attorney fees, USPTO filing fees, and related registration costs. The underlying research spending was already expensed and doesn’t come back onto the balance sheet. For a standard utility patent, those direct costs typically run from around $5,000 to $20,000 or more depending on the complexity of the invention and the number of claims.
A company that spent $10 million developing a breakthrough technology may still record the resulting patent at roughly $12,000 in legal costs. The patent is then amortized over its useful life, which cannot exceed the 20-year legal term for utility patents.4USPTO. 2701 – Patent Term Costs of defending a patent in litigation can also be capitalized, but only if the defense is expected to succeed and the outcome would increase the patent’s value; a losing defense means those costs get written off. A patent purchased from a third party is recorded at its purchase price.
Acquired In-Process R&D
The treatment flips when unfinished research is acquired through a business combination. Ongoing projects from an acquired company are recorded at fair value as indefinite-lived intangible assets on the acquirer’s balance sheet. The purchase transaction supplies an objective, market-based measure of value that internal spending cannot.
Valuation experts typically estimate the projects’ worth using projected future cash flows adjusted for the probability of technical and commercial success. If a company pays $50 million for an acquisition and the valuation attributes $10 million to in-process R&D, that $10 million sits on the balance sheet as a separate intangible asset. Because the projects aren’t complete, they aren’t amortized. Instead, they require annual impairment testing, plus interim testing whenever events suggest impairment, such as unfavorable clinical trial results or a competitor reaching the market first. When a project is finished, the asset is reclassified as finite-lived and begins amortizing. If a project is abandoned, the remaining value is written off as an impairment loss.
Software Development
Software is one of the few areas where GAAP allows some development costs to be capitalized. The treatment depends on whether the software is built for internal use or for sale.
For internal-use software, ASC 350-40 allows capitalization once management has authorized and committed to funding the project and it is probable the project will be completed and function as intended.5FASB. FASB Issues Standard That Makes Targeted Improvements to Internal-Use Software Guidance Costs incurred before that point, including those tied to unresolved technological uncertainties, are expensed. After the threshold is met, eligible internal and external costs are capitalized until the software is ready for its intended use.
Software built for sale or licensing follows ASC 985-20. All development costs are expensed until technological feasibility is established, and in practice that threshold is met late in the development cycle because it requires showing that high-risk development issues have been resolved through actual coding and testing. Most costs for externally marketed software therefore end up expensed. FASB has issued an update that consolidates and simplifies parts of this guidance, effective for annual periods beginning after December 15, 2027, with early adoption permitted.5FASB. FASB Issues Standard That Makes Targeted Improvements to Internal-Use Software Guidance
Financial Accounting Is Not Tax Accounting
How R&D is classified for financial reporting has nothing to do with how it is treated on a tax return. The two systems diverged sharply starting in 2022, when the Tax Cuts and Jobs Act required domestic R&D to be amortized over five years and foreign R&D over 15 years for tax purposes.6Internal Revenue Service. Revenue Procedure 2025-28 The One Big Beautiful Bill Act reversed that for domestic spending. Under new Section 174A, for tax years beginning after December 31, 2024, domestic research and experimental expenditures can once again be fully deducted in the year they are paid or incurred, or a company can elect to capitalize and amortize them over at least 60 months.7Office of the Law Revision Counsel. 26 USC 174A – Domestic Research or Experimental Expenditures Foreign research expenditures still amortize over 15 years under Section 174. None of that changes the balance sheet answer: for financial statement purposes, internal R&D is still expensed under GAAP and still split between research and development under IFRS.